Ultime notizie per FTAC Emerald (NASDAQ:FLDDU) Azioni

FTAC Emerald Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination, with one or more businesses or assets.

FTAC Emerald Acquisition Corp

WIIM

RVLV

Revolve Group shares are trading higher after the company reported better-than-expected Q3 financial results.

McVey has agreed to remain as the Chairman of the Board of Directors of MarketAxess Limited, the Company's international holding company.

News

Management

MKTX

MarketAxess Founder And Executive Chairman Rick Mcvey To Retire At Year-End; Carlos Hernandez Elected As Next Chairman

The quarterly dividend of $0.55 per common share is payable November 29, 2024, to stockholders of record at the close of business on November 15, 2024.&nbsp;

Dividends

Health Care

General

Cencora Declared A Quarterly Dividend Of $0.55 Per Common Share, An 8% Increase In Its Quarterly Dividend Rate From $0.51 Per Common Share

Guidance

Kennametal Sees Q2 Revenues Of $480M-$500M Vs. $492.97M Estimate; And Adjusted EPS Of $0.20-$0.30 Vs. $0.27 Estimate

HC Wainwright &amp; Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIU#NASDAQ">ACIU</a>) with a Buy and maintains $16 price target.

Price Target

Reiteration

Analyst Ratings

ACIU

HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) reported quarterly earnings of $3.34 per share which beat the analyst consensus estimate of $3.22 by 3.73 percent. This is a 16.78 percent increase over earnings of $2.86 per share from the same period last year. The company reported quarterly sales of $79.05 billion which beat the analyst consensus estimate of $77.65 billion by 1.80 percent. This is a 14.70 percent increase over sales of $68.92 billion the same period last year.

Earnings

Cencora Q4 2024 Adj EPS $3.34 Beats $3.22 Estimate, Sales $79.05B Beat $77.65B Estimate

Bookings were $3.82 billion, representing a book-to-bill ratio of 104.4% or 109.3% on a trailing twelve-month basis.&nbsp;
Bookings were $3.82 billion, representing a book-to-bill ratio of 104.4% or 109.3% on a trailing twelve-month basis.
 &nbsp;

CGI's Q4 Bookings Were $3.82B For A Book-To-Bill Ratio Of 104.4%

The Company now expects its fiscal 2024 organic net sales and reported net sales outlooks towards the lower end of its previously stated ranges of organic net sales growth versus the prior year of -3% to -1% and reported net sales growth versus the prior year of -5% to -3%.&nbsp;

PRGO

Perrigo Now Expects FY24 Organic Net Sales And Reported Net Sales Outlooks Towards Lower End Of Its Previously Stated Ranges

Kennametal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMT#NYSE">KMT</a>) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $0.26 by 11.54 percent. The company reported quarterly sales of $481.948 million which missed the analyst consensus estimate of $484.074 million by 100.00 percent. This is a 100.00 percent decrease over sales of $492.476 million the same period last year.

Earnings Beats

Earnings Misses

Kennametal Q1 2025 Adj. EPS $0.29 Beats $0.26 Estimate, Sales $481.948M Miss $484.074M Estimate

GPUS

Hyperscale Data Announced That It Plans To Issue A $16.25M Stated Value Special Dividend of 10% Series E Cumulative Redeemable Perpetual Preferred Stock

Perrigo Reaffirms FY24 Adjusted EPS Outlook Of $2.50 - $2.65, Est $2.57

CVS shares are trading higher following a Q3 revenue beat.

Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) reported quarterly losses of $(2.44) per share which missed the analyst consensus estimate of $(1.01) by 141.58 percent. The company reported quarterly sales of $1.335 billion which beat the analyst consensus estimate of $1.329 billion by 0.44 percent.

LINE

Lineage Q3 2024 GAAP EPS $(2.44) Misses $(1.01) Estimate, Sales $1.335B Beat $1.329B Estimate

CGI Q4 2024 Adj. EPS C$1.92 Beats C$1.91 Estimate, Sales C$3.660B Beat C$3.609B Estimate

Perrigo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) reported quarterly earnings of $0.81 per share which missed the analyst consensus estimate of $0.82 by 1.22 percent. This is a 26.56 percent increase over earnings of $0.64 per share from the same period last year. The company reported quarterly sales of $1.09 billion which missed the analyst consensus estimate of $1.13 billion by 3.29 percent. This is a 3.20 percent decrease over sales of $1.12 billion the same period last year.

Perrigo Q3 2024 Adj EPS $0.81 Misses $0.82 Estimate, Sales $1.09B Miss $1.13B Estimate

Transaction Details
Cencora will acquire RCA for approximately $4.6 billion in cash, subject to a customary working capital and net-debt adjustment. RCA's affiliated practices, physicians and management will retain a minority interest in RCA, with Cencora holding approximately 85% ownership in RCA upon closing. Additionally, Cencora will potentially pay up to $500 million in aggregate contingent consideration in fiscal year 2027 and fiscal year 2028, subject to the successful completion of certain predefined business objectives.

Cencora Has Agreed To Acquire Retina Consultants Of America From Webster Equity Partners For Approximately $4.6B In Cash

Benchmark analyst David Williams reiterates Alpha &amp; Omega (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOSL#NASDAQ">AOSL</a>) with a Buy and maintains $40 price target.

AOSL

Benchmark Reiterates Buy on Alpha & Omega, Maintains $40 Price Target

MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $1.83 by 3.83 percent. The company reported quarterly sales of $206.715 million which beat the analyst consensus estimate of $206.245 million by 0.23 percent. This is a 19.99 percent increase over sales of $172.284 million the same period last year.

MarketAxess Holdings Q3 2024 GAAP EPS $1.90 Beats $1.83 Estimate, Sales $206.715M Beat $206.245M Estimate

CVS Health Q3 2024 Adj. EPS $1.09 Misses $1.53 Estimate, Sales $95.428B Beat $92.747B Estimate

Regis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGS#NYSE">RGS</a>) reported quarterly losses of $(0.36) per share. This is a 160 percent decrease over earnings of $0.60 per share from the same period last year. The company reported $46.06 million in sales this quarter. This is a 13.70 percent decrease over sales of $53.37 million the same period last year.

Comments

FTAC Emerald

Notizie

Ultime notizie per FTAC Emerald (NASDAQ:FLDDU) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO